Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 50, Issue 1, 2009, Pages 85-91

  Poiré, Xavier ^a   Artz, Andrew ^a   Larson, Richard A ^a   Kline, Justin ^a   Odenike, Olatoyosi ^a   Rich, Elizabeth ^a   Godley, Lucy ^a   Stock, Wendy ^a   van Besien, Koen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Alemtuzumab; Chronic myelogenous leukemia; Reduced intensity conditioning; Tyrosine kinase inhibitors

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; FLUDARABINE; IMATINIB; MELPHALAN; MITOXANTRONE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TACROLIMUS; VALACICLOVIR;

ADULT; ADVANCED CANCER; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIARRHEA; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; COMBINED MODALITY THERAPY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 59249089005     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802626624     Document Type: Article

References (35)

1. Hehlmann, R., Berger, U., Pfirrmann, M., Heimpel, H., Hochhaus, A. Hasford, J. et al. (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 109, pp. 4686-4692.
2. Zaretsky, Y., Rifkind, J., Lockwood, G., Tsang, R., Kiss, T. Hasegawa, W. et al. (2007) Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning. Bone Marrow Transplant, 40, pp. 423-430.
3. Oehler, V. G., Gooley, T., Snyder, D. S., Johnston, L., Lin, A. Cummings, C. C. et al. (2007) The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood, 109, pp. 1782-1789.
4. Radich, J. P., Olavarria, E. and Apperley, J. F. (2004) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am, 18, pp. 685-702.
5. Weisser, M., Schmid, C., Schoch, C., Hiddemann, W. and Kolb, H. J. (2005) Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML. Bone Marrow Transplant, 36, pp. 1017-1018.
6. Crawley, C., Szydlo, R., Lalancette, M., Bacigalupo, A., Lange, A. Brune, M. et al. (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood, 106, pp. 2969-2976.
7. Kebriaei, P., Detry, M. A., Giralt, S., Carrasco-Yalan, A., Anagnostopoulos, A. Couriel, D. et al. (2007) Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood, 110, pp. 3456-3462.
8. Morris, P. J. and Russell, N. K. (2006) Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation, 81, pp. 1361-1367.
9. Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D. Cook, G. et al. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, pp. 3865-3871.
10. Peggs, K. S., Sureda, A., Qian, W., Caballero, D., Hunter, A. Urbano-Ispizua, A. et al. (2007) Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol, 139, pp. 70-80.
11. Tauro, S., Craddock, C., Peggs, K., Begum, G., Mahendra, P. Cook, G. et al. (2005) Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol, 23, pp. 9387-9393.
12. van Besien, K., Artz, A., Smith, S., Cao, D., Rich, S. Godley, L. et al. (2005) Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol, 23, pp. 5728-5738.
13. Dann, E. J., Anastasi, J. and Larson, R. A. (1998) High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J Clin Oncol, 16, pp. 1498-1504.
14. O'Donnell, P., Artz, A., Undevia, S., Hart, J. and van Besien, K. (2008) Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplantation (alloHCT). J Clin Oncol, 26
15. Devine, S. M., Hoffman, R., Verma, A., Shah, R., Bradlow, B. A. Stock, W. et al. (2002) Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 99, pp. 2255-2258.
16. Kline, J., Pollyea, D. A., Stock, W., Artz, A., Rich, E. Godley, L. et al. (2006) Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant, 37, pp. 307-310.
17. Verma, A., Devine, S., Morrow, M., Chen, Y. H., Mihalov, M. Peace, D. et al. (2003) Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant, 31, pp. 813-816.
18. Sakiyama, M., Kami, M., Hori, A., Imataki, O., Hamaki, T. Murashige, N. et al. (2004) Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): Comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0. Bone Marrow Transplant, 34, pp. 787-794.
19. Akpek, G., Lee, S. J., Flowers, M. E., Pavletic, S. Z., Arora, M. Lee, S. et al. (2003) Performance of a new clinical grading system for chronic graft-versus-host disease: A multicenter study. Blood, 102, pp. 802-809.
20. Martino, R., Romero, P., Subira, M., Bellido, M., Altes, A. Sureda, A. et al. (1999) Comparison of the classic Glucksberg criteria and the IBMTR severity index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant, 24, pp. 283-287.
21. Thiede, C., Florek, M., Bornhauser, M., Ritter, M., Mohr, B. Brendel, C. et al. (1999) Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant, 23, pp. 1055-1060.
22. Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J. Kaeda, J. et al. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonising current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108, pp. 28-37.
23. Valcarcel, D., Martino, R., Sureda, A., Canals, C., Altes, A. Briones, J. et al. (2005) Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol, 74, pp. 144-151.
24. Lowdell, M. W., Craston, R., Ray, N., Koh, M., Galatowicz, G. and Prentice, H. G. (1998) The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplant, 21, pp. 679-686.
25. Thursky, K. A., Worth, L. J., Seymour, J. F., Miles Prince, H and Slavin, M. A. (2006) Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol, 132, pp. 3-12.
26. Chakrabarti, S., MacDonald, D., Hale, G., Holder, K., Turner, V. Czarnecka, H. et al. (2003) T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol, 121, pp. 109-118.
27. von dem Borne, P A, Beaumont, F., Starrenburg, C. W., Oudshoorn, M., Hale, G. Falkenburg, J. H. et al. (2006) Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica, 91, pp. 1559-1562.
28. Weisser, M., Tischer, J., Schnittger, S., Schoch, C., Ledderose, G. and Kolb, H. J. (2006) A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica, 91, pp. 663-666.
29. DeAngelo, D. J., Hochberg, E. P., Alyea, E. P., Longtine, J., Lee, S. Galinsky, I. et al. (2004) Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: Durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res, 10, pp. 5065-5071.
30. Olavarria, E., Ottmann, O. G., Deininger, M., Clark, R. E., Bandini, G. Byrne, J. et al. (2003) Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 17, pp. 1707-1712.
31. Savani, B. N., Montero, A., Kurlander, R., Childs, R., Hensel, N. and Barrett, A. J. (2005) Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant, 36, pp. 1009-1015.
32. Olavarria, E., Siddique, S., Griffiths, M. J., Avery, S., Byrne, J. L. Piper, K. P. et al. (2007) Post-transplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood, 110, pp. 4614-4617.
33. Goldman, J. M. (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood, 110, pp. 2828-2837.
34. Kujawski, L. and Talpaz, M. (2007) Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma, 48, pp. 2310-2322.
35. Valent, P. (2008) Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: Implications for the biology, management, and therapy of the disease. Br J Haematol